Association between the FCGR3A V158F polymorphism and the clinical response to infliximab in rheumatoid arthritis and spondyloarthritis patients

Scandinavian Journal of Rheumatology

Volumn 39, Issue 6, 2010, Pages 518-520

  Morales Lara, M J ^a   Conesa Zamora, P ^b   Garca Simon M S ^a   Pedrero, F ^a   Santaclara, V ^a   Perez Guillermo, M ^b   Soriano Navarro, E ^a  

^a Hospital Universitario Santa Maria Del Rosell   (Spain)

^b Hospital Universitario Santa Maria del Rosell   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB;

ALLELE; ANKYLOSING SPONDYLITIS; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE ASSOCIATION; DNA EXTRACTION; FCGR3A GENE; GENETIC POLYMORPHISM; GENOTYPE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; GENETIC ASSOCIATION STUDIES; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IGG; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING;

EID: 78649708666     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009741003781969     Document Type: Letter

References (10)

1. Arora T, Padaki R, Liu L, Hamburger AE, Ellison AR, Stevens SR, et al. Differences in binding and effector functions between classes of TNF antagonists. Cytokine 2009;45:124-31.
2. Kastbom A, Bratt J, Ernestam S, Lampa J, Padyukov L, Söderkvist P, et al. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis. Arthritis Rheum 2007;56:448-52.
3. Louis EJ, Watier HE, Schreiber S, Hampe J, Taillard F, Olson A, et al. Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study. Pharmacogenet Genomics 2006;16:911-14.
4. Canete JD, Suarez B, Hernandez MV, Sanmartí R, Rego I, Celis R, et al. Influence of variants of Fc{gamma}receptors IIA and IIIA on the ACR and EULAR responses to anti-TNF-alpha therapy in rheumatoid arthritis. Ann Rheum Dis 2009;68:1547-52.
5. Braun J, van der Heijde D, Doyle MK, Han C, Deodhar A, Inman R, et al. Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab. Arthritis Rheum 2009;61:1032-6.
6. Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 2006;108:2720-5.
7. Conesa-Zamora P, Santaclara V, Gadea-Ninoles E, Ortiz-Reina S, Perez-Guillermo M. Association of polymorphism in FcGR3A gene and progression of low-grade precursor lesions of cervical carcinoma. Hum Immunol 2010;71:314-17.
8. Ho P, Bruce IN, Silman A, Symmons D, Newman B, Young H, et al. Evidence for common genetic control in pathways of inflammation for Crohn's disease and psoriatic arthritis. Arthritis Rheum 2005;52:3596-602.
9. Wu J, Edberg JC, Redecha PB, Bansal V, Guyre PM, Coleman K, et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997;100:1059-70.
10. Kruithof E, Baeten D, De Rycke L, Vandooren B, Foell D, Roth J, et al. Synovial histopathology of psoriatic arthritis, both oligo-and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 2005;7: R569-80.